Coherus BioSciences Stock News

Coherus BioSciences (CHRS) and Shanghai Junshi Biosciences (SHJBF) esophageal cancer candidate toripalimab met co-primary endpoints in a phase 3 trial.

In last trading session, Coherus BioSciences Inc. (NASDAQ:CHRS) saw 0.65 million shares changing hands with its beta currently measuring 1.01. Company’s recent per share price level of $11.73 trading at $0.27 or 2.36% at ring of the bell on the day assigns it a market valuation of $939.46M. That closing price of CHRS’s stock is … Coherus BioSciences Inc. (NASDAQ:CHRS) Is 10.23% Above Its 52-Week Low, But How Long Will It Remain So? Read More »

Coherus BioSciences Inc''s (NASDAQ: CHRS ) Q4 net revenue was $73.4 million for Q4 FY21 compared to $110.4 million for the same period in 2020, missing estimates of $85.81 million. The decline was primarily due to a decrease in the number of units of Udenyca sold and a reduction in net realized price due to increased competition and COVID-19 impacts. The company posted an adjusted EPS … Full story available on Benzinga.com

Coherus BioSciences Inc's (NASDAQ: CHRS) Q4 net revenue was $73.4 million for Q4 FY21 compared to $110.4 million for the same period in 2020, missing estimates of $85.81 million. The decline was pr

CHRS earnings call for the period ending December 31, 2021.

Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q4 2021 Results - Earnings Call Transcript

Coherus BioSciences press release (CHRS): Q4 Non-GAAP EPS of -$0.46 beats by $0.08.Revenue of $73.37M (-33.6% Y/Y) misses by $9.24M.Cash and cash equivalents were $417.2 million as…

– YUSIMRY ™ (adalimumab-aqvh), Coherus’ second product, approved by FDA on December 17, 2021 – – BLAs under FDA review for PD-1 inhibitor toripalimab and CIMERLI ™ (ranibizumab-ranq) – – New FDA filings expected in 2022 for UDENYCA ® on-body injector and additional toripalimab indications – – UDENYCA ® delivered net sales of $73 million in 4Q 2021; $327 million in FY 2021 – – Conference call and webcast today at 5:00 p.m. ET –

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 1.64% and 11.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Coherus BioSciences (NASDAQ:CHRS) is scheduled to announce Q4 earnings results on Thursday, February 17th, after market close.The consensus EPS Estimate is -$0.54 (compared to $0.23 in…

REDWOOD CITY, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its fourth quarter and full year 2021 financial results will be r

Coherus Biosciences <> is set to close lower after JPMorgan analyst Christopher Schott slashed his price target on the biotech to $20 from $23 per share to imply a premium of ~62%

The COHERUS BIOSCIENCES POLITICAL ACTION COMMITTEE successfully filed their F3XN QUATERLY YEAR-END with the coverage period of 10/01/2021 to 12/31/2021 and a confirmation ID of FEC-1564749 *********CommitteeId: C00789370 | FilingId: 1564749 | FormType: F3XN | CoverageFrom: 10/01/2021 | CoverageThrough: 12/31/2021 | ReportType: QUATERLY YEAR-END*********

Coherus and Junshi Biosciences plan to evaluate the toripalimab + JS006 combination in clinical trials in multiple tumor types Combinations of PD-1 + TIGIT inhibitors have potential to expand checkpoint inhibitor utilization to new tumors and lines of therapy REDWOOD CITY, Calif., and SHANGHAI, China, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ: CHRS ) and Shanghai Junshi Biosciences Co., Ltd. ("Junshi Biosciences", HKEX: 1877; SSE: 688180) today announced that Coherus has initiated the process to exercise its option to license JS006, Junshi Biosciences'' TIGIT-targeted antibody, in the United States and Canada, expanding the companies'' 2021 immuno-oncology collaboration agreement. Coherus will pay Junshi Biosciences $35 million upfront, up to $255 million in development regulatory and sales milestones, and an 18% royalty on net product revenue, subject to terms and conditions agreed between the parties. Closing of the transaction is expected to follow receipt of any applicable regulatory clearances.